RSV Maternal Immunization vs. Monoclonal Antibodies: Comparing Immunity and Practical Differences

In this episode, Dr. Simões provides a detailed scientific comparison between maternal immunization and monoclonal antibody-based protection. Maternal immunization generates a polyclonal antibody response — a broad, naturally occurring array of antibodies directed against the whole pre-fusion F protein — that is transferred transplacentally to the infant as IgG. In addition, breastfeeding after maternal immunization confers a second layer of protection: IgA antibodies present in breast milk are uniquely absorbed by newborns (who lack gastric acid to destroy them) and reach mucosal surfaces directly. Dr. Simões notes that IgA receptor expression in the infant gut shuts off after the first year of life, making early breastfeeding particularly valuable.

Turning to pharmacokinetic differences between the two monoclonals, Dr. Simões explains that differences in half-life (approximately 65 days vs. 44 days) relate to the electrical charge on each antibody's surface, which affects distribution. Nirsevimab with the longer half-life remains in circulation longer, while clesrovimab distributes more actively into tissue, including lung. Both carry YTE modifications and are IgG class, and real-world effectiveness data do not yet demonstrate a meaningful clinical difference between them.

An important practical point is raised regarding upper respiratory tract protection: antibody concentrations in the nasal mucosa are far lower than in serum, and protecting the upper tract requires approximately 1,000 times the antibody level needed for lower tract protection. Emerging data suggest modest effects on otitis media prevention, but robust upper tract protection is unlikely with either monoclonal. The panel also agrees that neither strategy is likely to significantly reduce transmission or generate population-level herd protection.

In the next episode, "RSV Monoclonal Antibody Resistance: What Clinicians Need to Know," Dr. Simões reviews the emerging concern of resistance mutations — and what surveillance data are telling us about the long-term durability of these protections.